$MAZE News

Maze Therapeutics to Participate in Three Upcoming Investor Conferences

Maze Therapeutics: Intriguing Kidney Disease Assets Put This On The Watchlist

Maze Therapeutics Announces Appointments to Its Board of Directors

BTIG Reiterates Buy on Maze Therapeutics, Maintains $46 Price Target

Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Maze Therapeutics Q2 EPS $(0.76) Misses $(0.73) Estimate

Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect?

What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?

Maze Therapeutics Phase 2 Kidney Data Sparks Questions On Upside And Risk

Maze Therapeutics, Inc. (MAZE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Maze Therapeutics (MAZE): 8 Oversold Stocks to Buy Right Now

Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors?

Maze Therapeutics to Participate in Two Upcoming Investor Conferences

Industry Analysts Just Made A Stunning Upgrade To Their Maze Therapeutics, Inc. (NASDAQ:MAZE) Revenue Forecasts

Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates

Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Maze Therapeutics Q1 EPS $(0.45) Beats $(0.56) Estimate, Sales $20.000M Beat $9.286M Estimate

A Look At Maze Therapeutics (MAZE) Valuation After Recent Share Price Weakness

Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials

What Makes Maze Therapeutics (MAZE) One of the Best Oversold Small-Cap Stocks to Buy